Home > E. Pathology by systems > Respiratory system > Lungs > Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth (...)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Thursday 17 October 2013

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Small cell lung cancer (SCLC) transformation during epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in lung cancer

Small cell lung cancer (SCLC) transformation during epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in lung cancer has been suggested as one of possible resistance mechanisms.

Open references

- Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Chang Y, Kim SY, Choi YJ, So KS, Rho JK, Kim WS, Lee JC, Chung JH, Choi CM. Tuberc Respir Dis (Seoul). 2013 Sep;75(3):95-103. PMID: #24101933#

- Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature. Sakai Y, Yamasaki T, Kusakabe Y, Kasai D, Kotani Y, Nishimura Y, Itoh T. Multidiscip Respir Med. 2013 Jul 18;8(1):47. doi:10.1186/2049-6958-8-47 . PMID: #23866929#

- Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma. Yanagisawa S, Morikawa N, Kimura Y, Nagano Y, Murakami K, Tabata T. Respirology. 2012 Nov;17(8):1275-7. doi:10.1111/j.1440-1843.2012.02258.x. PMID: #22943430#

References

- Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Popat S, Wotherspoon A, Nutting CM, Gonzalez D, Nicholson AG, O’Brien M. Lung Cancer. 2013 Apr;80(1):1-4. doi:10.1016/j.lungcan.2012.12.019 . PMID: #23312887#